title: Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
abstract: BACKGROUND
  The administration of intraperitoneal (IP) chemotherapy as first-line adjuvant treatment for women with optimally debulked advanced ovarian malignancy results in improved median and overall survival when compared with intravenous (IV) chemotherapy. However, the number of adverse events and toxicities are increased in patients treated with IP chemotherapy. In addition, the administration of IP chemotherapy is technically more challenging and the schedule is more demanding in terms of time and resources.
  
  
  OBJECTIVE
  We report on our initial experience with the administration of IP chemotherapy at two gynaecological oncology units in Australia.
  
  
  METHODS
  We collected retrospective data from a series of 23 women undergoing IP chemotherapy as adjuvant treatment for advanced ovarian cancer. In addition to standard (Common Terminology Criteria for Adverse Events v3.0, CTCAE) toxicity data, we collected technical data specific to the administration of IP chemotherapy.
  
  
  RESULTS
  The average number of IP chemotherapy cycles received was 4.3. Forty-three per cent of patients received all six planned IP chemotherapy cycles. Thirty-nine per cent of patients discontinued their IP treatment. Of those, 22% were discontinued because of drug-related toxicities and the remaining 17% experienced a port complication or toxicity directly related to the route of administration.
  
  
  CONCLUSIONS
  This study demonstrates the feasibility and practicality of and lessons learned from initial experiences with IP chemotherapy for ovarian cancer in Australia.
authors.affiliation: Department of Obstetrics and Gynaecology, The Royal Hobart Hospital, Hobart, Tasmania. michael.bunting@hnehealth.nsw.gov.au
authors.forename: Michael
authors.initials: M
authors.lastname: Bunting
authors.forename: Warren
authors.initials: W
authors.lastname: Chan
authors.forename: Alison
authors.initials: A
authors.lastname: Brand
authors.forename: Penelope
authors.initials: P
authors.lastname: Blomfield
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001315:Australia; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel; D002945:Cisplatin